BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11899651)

  • 21. A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
    Hunsinger V; Marchac AC; Derder M; Hivelin M; Lecuru F; Bats AS; Lantieri L
    Ann Chir Plast Esthet; 2016 Jun; 61(3):177-82. PubMed ID: 26946931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA mutation genetic testing implications in the United States.
    Bayraktar S; Arun B
    Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
    Perabò M; Fink V; Günthner-Biller M; von Bodungen V; Friese K; Dian D
    Arch Gynecol Obstet; 2014 Jun; 289(6):1325-30. PubMed ID: 24389920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of management of southern Chinese BRCA mutation carriers.
    Kwong A; Wong CH; Shea C; Suen DT; Choi CL
    World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
    Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
    Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
    Khansa I; Wang D; Coriddi M; Tiwari P
    Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.
    Olopade OI; Artioli G
    Breast J; 2004; 10 Suppl 1():S5-9. PubMed ID: 14984481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hereditary breast cancer].
    Schlehe B; Schmutzler R
    Chirurg; 2008 Nov; 79(11):1047-54. PubMed ID: 18854964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic bilateral mastectomy for breast cancer prevention.
    Metcalfe KA
    J Womens Health (Larchmt); 2004 Sep; 13(7):822-9. PubMed ID: 15385076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
    van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
    J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
    Batista LI; Lu KH; Beahm EK; Arun BK; Bodurka DC; Meric-Bernstam F
    BMC Cancer; 2008 Apr; 8():101. PubMed ID: 18410690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and genetic testing for breast cancer: variations in medical decisions.
    Bouchard L; Blancquaert I; Eisinger F; Foulkes WD; Evans G; Sobol H; Julian-Reynier C
    Soc Sci Med; 2004 Mar; 58(6):1085-96. PubMed ID: 14723904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options].
    Scheufler O; Fritschen Uv
    Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.